DIA & Vifor Pharma

July 8, 2019

Our latest white paper discusses the dynamics and marketing of 2018’s top selling drugs, chief therapeutic areas, and biosimilar erosion, with a deeper dive into the top three drugs: Humira, Revlimid, and Opdivo.

Spotlight

Curium Pharma

Curium is a world-class nuclear medicine solutions provider with over 100 years of industry experience. We service over 14 million patients worldwide each year and strive to provide best-in-class products and exceptional, reliable service.

OTHER WHITEPAPERS
news image

Modernizing Pharma Operations With Process Analytical Technology

whitePaper | November 18, 2022

It’s the same for manufacturers across industries and across the globe; there’s a steadily increasing pressure to meet market demand, despite facing new challenges andconstraints.

Read More
news image

Advancing drug development using in silico modeling

whitePaper | June 22, 2022

The technologic and pharmacologic advances that have enabled researchers to take aim at previously untreatable diseases have contributed to an increase in the number of molecules in the development pipeline that are challenging and difficult to manufacture.

Read More
news image

Benefits of Semantic Enrichment Across the Drug Development Pipeline

whitePaper | January 24, 2022

Semantics is the process of assigning meaning to words and is a vital step in making unstructured scientific content machine readable, contextualizing otherwise unstructured information. It unlocks a host of benefits to search and analytics which are outlined below in the context of use cases relevant to drug discovery.

Read More
news image

Overcoming Pharma’s Launch Performance Problem

whitePaper | March 24, 2023

The prescription medicine market recovered from the wild swings of the early pandemic with renewed volume growth, driven by generics. COVID-19 vaccines and treatments have created a substantial market.

Read More
news image

Employing Singleuse Technology to Control Frozen Bulk Drug Storage

whitePaper | September 29, 2022

New biopharmaceutical drug products that alter and even save lives can be very profitable for their developers.

Read More
news image

Potential measures to facilitate the productions of activepharmaceutical ingredients (APIs)

whitePaper | March 27, 2023

European countries have been experiencing medicine shortages due to disruptions in the supply chain. Reshoring the productions of active pharmaceutical ingredients (APIs) is considered as an approach to secure the supply.

Read More

Spotlight

Curium Pharma

Curium is a world-class nuclear medicine solutions provider with over 100 years of industry experience. We service over 14 million patients worldwide each year and strive to provide best-in-class products and exceptional, reliable service.

Events